Jeremy Grantham's PFE Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 2.38 M shares of Pfizer Inc. (PFE) worth $59.24 M, representing 0.15% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2016, adding 6.48 M shares. Largest reduction occurred in Q4 2013, reducing 20.92 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -42,293 | Reduce 1.75% | 2.38 M | $24.90 |
| Q3 2025 | -133,144 | Reduce 5.21% | 2.42 M | $25.48 |
| Q2 2025 | -325,720 | Reduce 11.31% | 2.55 M | $24.24 |
| Q1 2025 | +203,388 | Add 7.60% | 2.88 M | $25.34 |
| Q4 2024 | +464,885 | Add 21.02% | 2.68 M | $26.53 |
| Q3 2024 | -408,161 | Reduce 15.58% | 2.21 M | $28.94 |
| Q2 2024 | +174,969 | Add 7.16% | 2.62 M | $27.98 |
| Q1 2024 | -150,264 | Reduce 5.79% | 2.45 M | $27.75 |
| Q4 2023 | +321,372 | Add 14.13% | 2.6 M | $28.79 |
| Q3 2023 | +339,589 | Add 17.56% | 2.27 M | $33.17 |
| Q2 2023 | +479,118 | Add 32.92% | 1.93 M | $36.68 |
| Q1 2023 | +338,600 | Add 30.32% | 1.46 M | $40.80 |
| Q4 2022 | +306,770 | Add 37.88% | 1.12 M | $51.24 |
| Q3 2022 | -9,662 | Reduce 1.18% | 809,860 | $43.76 |
| Q2 2022 | +636,200 | Add 347.04% | 819,522 | $52.43 |
| Q1 2022 | -174,323 | Reduce 48.74% | 183,322 | $51.77 |
| Q4 2021 | -457,535 | Reduce 56.13% | 357,645 | $59.05 |
| Q3 2021 | +54,450 | Add 7.16% | 815,180 | $43.01 |
| Q2 2021 | +381,545 | Add 100.62% | 760,730 | $39.16 |
| Q1 2021 | +214,000 | Add 129.55% | 379,185 | $36.23 |
| Q4 2020 | -20,500 | Reduce 11.04% | 165,185 | $36.81 |
| Q3 2020 | +2,500 | Add 1.36% | 185,685 | $36.70 |
| Q2 2020 | -95,338 | Reduce 34.23% | 183,185 | $32.70 |
| Q1 2020 | -95,286 | Reduce 25.49% | 278,523 | $32.64 |
| Q4 2019 | -166,040 | Reduce 30.76% | 373,809 | $39.18 |
| Q3 2019 | +23,707 | Add 4.59% | 539,849 | $35.93 |
| Q2 2019 | +5,295 | Add 1.04% | 516,142 | $43.32 |
| Q1 2019 | -267,032 | Reduce 34.33% | 510,847 | $42.47 |
| Q4 2018 | -252,253 | Reduce 24.49% | 777,879 | $43.65 |
| Q3 2018 | -1.96 M | Reduce 65.52% | 1.03 M | $44.07 |
| Q2 2018 | -1.29 M | Reduce 30.24% | 2.99 M | $36.28 |
| Q1 2018 | +262,816 | Add 6.54% | 4.28 M | $35.49 |
| Q4 2017 | -121,500 | Reduce 2.93% | 4.02 M | $36.22 |
| Q3 2017 | -642,580 | Reduce 13.43% | 4.14 M | $35.70 |
| Q2 2017 | -2,812 | Reduce 0.06% | 4.78 M | $33.59 |
| Q1 2017 | -665,232 | Reduce 12.20% | 4.79 M | $34.21 |
| Q4 2016 | -1.27 M | Reduce 18.84% | 5.45 M | $32.48 |
| Q3 2016 | -5.56 M | Reduce 45.31% | 6.72 M | $33.87 |
| Q2 2016 | +6.48 M | Add 111.72% | 12.28 M | $35.21 |
| Q1 2016 | -177,224 | Reduce 2.96% | 5.8 M | $29.64 |
| Q4 2015 | -315,499 | Reduce 5.01% | 5.98 M | $32.28 |
| Q3 2015 | +302,198 | Add 5.04% | 6.29 M | $31.41 |
| Q2 2015 | +5.96 M | Add 18003.62% | 5.99 M | $33.53 |
| Q1 2015 | -836 | Reduce 2.46% | 33,095 | $34.78 |
| Q4 2014 | -1.08 M | Reduce 96.95% | 33,931 | $31.15 |
| Q3 2014 | +761,946 | Add 218.01% | 1.11 M | $29.57 |
| Q2 2014 | -6.39 M | Reduce 94.82% | 349,508 | $29.68 |
| Q1 2014 | -20.06 M | Reduce 74.85% | 6.74 M | $32.12 |
| Q4 2013 | -20.92 M | Reduce 43.84% | 26.8 M | $30.63 |
| Q3 2013 | -10.3 M | Reduce 17.75% | 47.73 M | $28.71 |
| Q2 2013 | +58.02 M | Add 0.00% | 58.02 M | $28.01 |
Jeremy Grantham's Pfizer Investment FAQs
Jeremy Grantham first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 58,022,697 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Pfizer Inc. (PFE) for 51 quarters since Q2 2013.
Jeremy Grantham's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 58,022,697 shares worth $1.63 B.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 2,378,969 shares of Pfizer Inc. (PFE), valued at approximately $59.24 M.
As of the Q4 2025 filing, Pfizer Inc. (PFE) represents approximately 0.15% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Pfizer Inc. (PFE) was 58,022,697 shares, as reported at the end of Q2 2013.